A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
BACKGROUND: The purpose of this study was to explore how semaglutide, a GLP-1RA, regulates serum metabolism and gut microbiota to improve obesity in mice and whether fecal microbiota transplantation (FMT) can transmit the beneficial effects of semagl…
BACKGROUND: Paediatric obesity is a global public health concern. While in most countries the incidence keeps rising, the need for effective and long-term management for children and adolescents living with this chronic, relapsing disease is pressing…
BACKGROUND: Renal ischemia-reperfusion injury (RIRI) is a major cause of acute kidney injury, with endothelial dysfunction playing a central role in its pathophysiology. However, the molecular mechanisms underlying endothelial damage during RIRI rema…
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for glycemic control and weight loss, but their effects on surgical outcomes remain incompletely understood. Delayed gastric emptying and associated perio…
RATIONALE: Alcohol use disorder (AUD) remains a major public health challenge, yet effective pharmacotherapies are limited. As such, there is growing interest in repurposing medications with novel mechanisms of action. Glucagon-like peptide-1 (GLP-1)…
AIMS: One of the recent growing complications of neoplastic chemotherapy that is considered a challenge in their therapeutic protocol is testicular dysfunction. The pathogenesis of testicular injury is multifactorial, involving various pathogenic mec…
Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 RAs) are widely used as antidiabetic and anti-obesity agents. Although conventional GLP-1 RAs, such as liraglutide and semaglutide, are acylated with fatty acids to delay their degradation by d…
The ground-breaking development of the incretin agonists by manipulation of the incretin system, including the gut hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), as well as the pancreatic hormone gluc…
Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated efficacy for weight loss and glycemic control in patients with obesity and type 2 diabetes mellitus, but data are limited for patients with end-stage kidney disease on dialysis…
BACKGROUND AND AIMS: In the FLOW trial, semaglutide reduced the risks of kidney and cardiovascular (CV) outcomes and death in participants with type 2 diabetes and chronic kidney disease (CKD). These prespecified analyses assessed the effects of sema…
Treatment of patients with chronic kidney disease (CKD) requires implementation of prevention and management strategies that reduce the risk of kidney failure and CKD-associated cardiovascular risk. Metabolic syndrome is characterized by obesity, hig…
INTRODUCTION AND OBJECTIVES: There is still limited evidence on the role of glucagon-like peptide-1 receptor agonists in heart failure. We analyzed the efficacy in terms of health status, and the change in body weight of once-weekly semaglutide in pa…
Skeletal muscle is the largest insulin-sensitive tissue in the human body, playing a crucial role in glucose homeostasis, body mobility and overall metabolic health. In obesity and type 2 diabetes (T2D), skeletal muscle undergoes structural, function…
Salcaprozate sodium (SNAC) is a clinically approved oral permeation enhancer, notably used in the formulation of oral semaglutide. Despite its pharmaceutical importance, the crystallographic information of SNAC or its free acid form, salcaprozoic aci…
BACKGROUND: The SELECT trial found semaglutide reduced major adverse cardiovascular events (MACE) in patients with overweight or obesity with cardiovascular disease but without diabetes. We report a prespecified analysis of the SELECT trial on the re…
OBJECTIVE: Obesity is a biologically complex and heterogeneous disease that requires individualized, phenotype- and complication-oriented therapeutic strategies. The introduction of advanced pharmacotherapies, including GLP-1 receptor agonists (GLP-1…
BACKGROUND: The aim of the present study was to assess the cost-effectiveness of bariatric surgery, non-surgical weight loss and pharmacological non-surgical weight loss (BS-WL, NS-WL, PNS-WL) to avoid or delay total knee arthroplasty (TKA) in subjec…
OBJECTIVE: This systematic review aimed to assess the efficacy and safety of GLP-1 RAs in adults with obesity or overweight, by comparing different GLP-1 RAs, identifying the most effective agents, and evaluating adverse effects. METHODS: We systemat…